Market Intelligence, Clinical Progress, and High-Purity Reagents for Wnt Pathway Inhibition & ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FZD8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FZD8 CRD-ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed for native disulfide bond formation. |
View FZD8 Products |
| Gene Delivery | FZD8 Promise-ORF / Lentivirus Premade Particles Full-length 7TM construct for stable cell line generation. Native glycosylation preservation. |
View FZD8 Products |
| Benchmark Ab | Anti-FZD8 (Sequence of Ipafricept-competing clone) Recombinant positive control for binding competition assays. |
View FZD8 Products |
| Validator | FZD8 siRNA Set (Triple pack) For knockdown verification and specificity controls. |
View FZD8 Products |
| Related Target: FZD5 | FZD5 CRD-ECD-Fc Protein Closest homolog (73% CRD identity). Essential for selectivity counter-screening. |
View FZD5 Products |
| Related Target: LRP6 | LRP6 E1-E2 Domain Protein Wnt co-receptor. Required for ternary complex formation assays. |
View LRP6 Products |
| Related Target: WNT3A | WNT3A Recombinant Protein Ligand for binding competition and reporter assays. |
View WNT3A Products |
Critical Assay Challenges & Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Family Selectivity (FZD1/2/5/7 cross-reactivity) | Frizzled Homolog Panel: FZD1, FZD2, FZD5, FZD7, FZD8 CRD proteins strictly verified by mass spec; >95% purity for accurate SPR/BLI off-rate screening |
| Cross-species Cyno/Mouse eval for IND-enabling | Human/Mouse/Cyno FZD8 ortholog proteins available with matched ECD boundaries; Theoretical MW confirmed by SDS-PAGE |
| GPCR Conformation Integrity (7TM) | Lentivirus Particles for Stable Cell Line generation: Preserves native membrane topology and glycosylation; Endotoxin controlled |
| ADC Internalization Efficiency | Full-length FZD8 Lentivirus + Anti-FZD8 Antibody pair validated for flow cytometry-based internalization quantification |
| Lack of Controls | Clinical Benchmark Antibodies (Ipafricept-competing sequences) included as binding references |
| False Positives in Binding | Validated siRNA included for target-specificity verification in functional assays |
Live FZD8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FZD8 therapeutics is intensifying, with major players shifting focus from broad Wnt pathway inhibition to selective FZD8 blockade. As a 7-transmembrane GPCR critical in cancer stem cell maintenance and tumor microenvironment modulation, FZD8 represents a high-value target. First-generation decoy receptor strategies (e.g., Ipafricept) validated the target but revealed dose-limiting bone toxicities associated with pan-Frizzled inhibition. The next wave of R&D targets antibody-drug conjugates (ADCs) leveraging FZD8 internalization properties in pancreatic and gastric malignancies, along with bispecific formats (FZD8 x CD3/PD-1) and combination regimens with immune checkpoint inhibitors. Specificity remains paramount to avoid off-target effects on FZD1/2/4/5.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Decoy Receptor (Fc-Fusion) | Leap Therapeutics (Ipafricept), OncoMed | Solid Tumors (Pancreatic, Gastric) | Binary/ternary complex formation (Need FZD8 + LRP6 proteins); Competition ELISA |
| ADC | Emerging Biotechs (Undisclosed) | FZD8-high Cancers (CRC, TNBC) | Internalization Assay (Need full-length FZD8 Lentivirus cell lines) |
| Bispecific mAb | Preclinical Labs | Immunotherapy combinations | Cross-reactivity panel (Need FZD5/FZD8 selectivity verification) |
| Monoclonal Antibody | Academic Consortia | Fibrosis, Regeneration | Epitope mapping (Need CRD subdomain fragments) |
| Small Molecules | Various (Porcupine/Wnt Pathway) | Advanced Solid Tumors | Downstream signaling reporter lines (Need FZD8 Lentivirus) |